Business
Ventripoint Diagnostics Begins Publication of Case Studies Showing Meritorious Use of the VMS Heart Analysis System
(TheNewswire) Toronto, Ontario – TheNewswire – April 13, 20...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Diagnostics Begins Publication of Case Studies Showing Meritorious Use of the VMS Heart Analysis System\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario – TheNewswire –\nApril 13, 2021\n \n \n - Ventripoint Diagnostics Ltd.\n(\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"), (TSXV:VPT\n \n \n )\n \n \n ;\n \n \n (\n \n \n OTC:VPTDF) has published its first case study of the\nmeritorious use of the Ventripoint VMS whole-heart analysis system\n(\n \n \n \n \n https://www.ventripoint.com/whitepapers-case-studies\n \n \n \n \n \n )\n \n \n \n in routine\nclinical practice.\n \n \n \n \n Dr. Gregory Skinner at East Midlands Congenital Heart\nCentre, Leicester, England documents a case of two patients with\nTetralogy of Fallot (ToF), which developed significant right\nventricular (RV) dilation due to pulmonary valve dysfunction.  The\ncase studies highlight the need for repeated accurate assessments of\nRV size and function to determine the optimal time for valve\nreplacement and evaluate the outcome.  The remodeling of the RV\ntowards a normal size after surgical implantation of the pulmonary\nvalve signifies the RV has not been left too long in the dilated\nstate.  In one case the RV remodeled (shrunk) and in the other case\nit did not.\n \n \n \n \n A series of case studies and white papers will be\npublished over the next several months to showcase various limitations\nof current clinical practice, which are overcome by the VMS family of\nproducts.  Coming topics include user experience perspectives,\nusability of the VMS products, and VMS use in patients infected with\nCOVID-19.\n \n \n \n \n About Ventripoint Diagnostics\nLtd.\n \n \n \n \n Ventripoint\n \n \n has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary KBR technology, which is the result of a decade of\ndevelopment and provides accurate volumetric cardiac measurements\nequivalent to MRI. This affordable, gold-standard alternative allows\ncardiologists greater confidence in the management of their patients.\nProviding better care to patients serves as a springboard and basic\nstandard for all of Ventripoint's products that guide our future\ndevelopments. In addition, VM...